CompletedPhase 3
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
Key facts
- Who runs it
- Jinnah Hospital
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 30 people enrolled
- Started
- 1 Jul 2023
- Ended
- 16 Jan 2024
- Type of study
- Interventional
- Treatments tested
- Tofacitinib
- Record updated
- 26 February 2024
Who can take part
- Age
- 15 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients presenting with Alopecia areata as per operational definition will be included in the study
- Either gender
- Age 15 - 60 years
Who cannot take part
- Patients having history of treatment with systemic agents, having active infection, pregnant and lactating women and patients having severe hematological abnormalities
- Patient with history of connective tissue disorders, vasculitis, seropositive and seronegative arthritis
- Patients positive for latent infections
- Patients with weight <25 kg
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan. Efficacy of treatment in patients presenting with alopecia areata will be assessed using SALT Score on follow up at 6,12 and 24 weeks where four categories of treatment response were defined: 0 (re-growth ≤10%), 1 (11-25%), 2 (26-50%), 3 (51-75%) and 4 (re-growth >75%). Efficacy will be considered if re-growth ≥ 2.
The group in the trial
- TofacitinibTreatment being tested
tofacitinib 5mg twice daily for 6 months
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 26 February 2024